Pfizer's ABRYSVO is an RSV vaccine approved for use in various populations, including adults aged 60 and older, pregnant individuals between 32 and 36 weeks gestation, and adults aged 18 through 59 who are at increased risk for RSV-related lower respiratory tract disease.